Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to eight newly-hired employees. The inducement grants total 148,000 shares of common stock with an exercise price of $2.41 per share, matching the closing price on April 30, 2025. The options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia.
Akebia Therapeutics (NASDAQ: AKBA), un'azienda biofarmaceutica specializzata in trattamenti per le malattie renali, ha concesso opzioni su azioni a otto nuovi dipendenti. Le concessioni di incentivazione ammontano a un totale di 148.000 azioni ordinarie con un prezzo di esercizio di 2,41 dollari per azione, corrispondente al prezzo di chiusura del 30 aprile 2025. Le opzioni prevedono un piano di maturazione di 4 anni, con il 25% delle azioni che maturano dopo il primo anno e il restante 75% che matura trimestralmente successivamente. Ogni opzione ha una durata di 10 anni ed è subordinata alla continuazione del rapporto di lavoro con Akebia.
Akebia Therapeutics (NASDAQ: AKBA), una compañía biofarmacéutica enfocada en tratamientos para enfermedades renales, ha otorgado opciones sobre acciones a ocho empleados recién contratados. Las concesiones de incentivos suman un total de 148,000 acciones ordinarias con un precio de ejercicio de $2.41 por acción, igualando el precio de cierre del 30 de abril de 2025. Las opciones cuentan con un programa de adquisición de derechos de 4 años, con el 25% que se adquiere después del primer año y el 75% restante que se adquiere trimestralmente después. Cada opción tiene un plazo de 10 años y depende de la continuidad laboral con Akebia.
Akebia Therapeutics (NASDAQ: AKBA)는 신장 질환 치료에 중점을 둔 바이오제약 회사로, 새로 채용된 8명의 직원에게 주식 매수선택권을 부여했습니다. 인센티브 부여는 총 148,000주의 보통주로, 행사 가격은 2025년 4월 30일 종가인 주당 2.41달러와 동일합니다. 옵션은 4년 베스팅 스케줄로, 첫 해 후 25%가 베스팅되며 나머지 75%는 분기별로 베스팅됩니다. 각 옵션의 유효 기간은 10년이며, Akebia에서 계속 근무하는 조건에 따라 유효합니다.
Akebia Therapeutics (NASDAQ : AKBA), une société biopharmaceutique spécialisée dans les traitements des maladies rénales, a accordé des options d'achat d'actions à huit nouveaux employés. Les attributions d'incitation totalisent 148 000 actions ordinaires avec un prix d'exercice de 2,41 $ par action, correspondant au cours de clôture du 30 avril 2025. Les options suivent un calendrier d'acquisition de droits sur 4 ans, avec 25 % acquis après la première année et les 75 % restants acquis trimestriellement par la suite. Chaque option a une durée de 10 ans et dépend de la poursuite de l'emploi chez Akebia.
Akebia Therapeutics (NASDAQ: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Nierenerkrankungen spezialisiert hat, hat Aktienoptionen an acht neu eingestellte Mitarbeiter vergeben. Die Anreizzuteilungen umfassen insgesamt 148.000 Aktien mit einem Ausübungspreis von 2,41 USD pro Aktie, entsprechend dem Schlusskurs vom 30. April 2025. Die Optionen haben einen 4-jährigen Vesting-Zeitplan, wobei 25 % nach dem ersten Jahr und die restlichen 75 % danach vierteljährlich vesten. Jede Option hat eine Laufzeit von 10 Jahren und ist an eine fortgesetzte Beschäftigung bei Akebia gebunden.
- None.
- None.
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of Akebia’s common stock on April 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What stock options did Akebia Therapeutics (AKBA) grant to new employees in April 2025?
What is the vesting schedule for AKBA's April 2025 employee stock options?
What was the exercise price for Akebia Therapeutics' April 2025 inducement grants?
How long is the term of the stock options granted by AKBA in April 2025?
